Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

biotech

InnoCare licensing deal

InnoCare licensing deal flops due to lack of upfront cash

The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
October 16, 2025
9969.HK 688428.SHG

BRIEF: ImmuneOnco to raise $45 million via share placement at 13% discount

Innovative drug developer ImmuneOnco (1541.HK) announced on Thursday that it plans to place 24.2 million new shares, representing about 5.61% of its enlarged share capital, to raise HK$351 million ($45…
October 9, 2025
1541.HK
Obesity drug maker Sciwind IPO

Obesity drug maker Sciwind targets IPO, with heavyweight backers

Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition Key Takeaways: • Clinical…
October 9, 2025
A wild ride for TransThera investors

A wild ride for TransThera investors: what’s the story?

The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
September 25, 2025
2617.HK

INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback

The administration of U.S. President Donald Trump is weighing restrictions on the import of drugs and experimental therapies from China, a move that could disrupt the U.S. pharmaceutical industry and…
September 11, 2025
Zai Lab under pressure over clinical results and rival drugs

Zai Lab under pressure over clinical results and rival drugs

Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
September 11, 2025
9688.HK ZLAB.US
Akeso shares take a hit

Akeso shares take a hit despite surging sales of cancer drugs

The maker of oncology drugs posted higher half-year revenues but a widening net loss and share sales by its founders have dented investor confidence Key Takeaways: Drug sales rose 49%…
September 4, 2025
9926.HK
Load more

Recent Articles

InnoCare licensing deal
October 16, 2025

InnoCare licensing deal flops due to lack of upfront cash

9969.HK 688428.SHG
October 9, 2025

BRIEF: ImmuneOnco to raise $45 million via share placement at 13% discount

1541.HK
October 9, 2025

Obesity drug maker Sciwind targets IPO, with heavyweight backers

September 25, 2025

A wild ride for TransThera investors: what’s the story?

2617.HK
September 11, 2025

INDUSTRY BRIEF: Trump eyes curbs on Chinese drugs, drawing industry pushback

September 11, 2025

Zai Lab under pressure over clinical results and rival drugs

9688.HK ZLAB.US
September 4, 2025

Akeso shares take a hit despite surging sales of cancer drugs

9926.HK

RELATED ARTICLES

  1. Kelun-Biotech reported rising sales of its signature cancer drug
    August 28, 2025
    Precision cancer drugs show promise for Kelun-Biotech
    6990.HK
  2. July 10, 2025
    RemeGen’s $4.2 billion licensing deal falls flat with investors
    9995.HK 688331.SHG
  3. May 29, 2025
    3SBio hits the big time with $6 billion cancer drug deal
    1530.HK
  4. July 3, 2025
    HBM notches up another mega deal but is the model sustainable?
    2142.HK
  5. August 15, 2025
    XtalPi scores landmark deal for AI drug discovery
    2228.HK
  6. June 12, 2025
    CSPC Pharma teases big bucks deals after earnings miss
    1093.HK
  7. June 19, 2025
    Alphamab stake sale could signal harder times ahead
    9966.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.